Please login to the form below

Not currently logged in
Email:
Password:

Eurocine Vaccines appoints chief scientific officer and chief business officer

Anna-Karin Maltais and Emma Berglund both receive promotions

Eurocine Vaccines has appointed Dr Anna-Karin Maltais as chief scientific officer and promoted business development manager Emma Berglund to chief business officer.

Dr Maltais, who also becomes head of R&D, takes over from Professor Jorma Hinkula, who has returned to his previous position as professor at the University of Linköping in Sweden.

In her new role, Dr Maltais will oversee Eurocine's vaccines development programme, which includes Immunose – a nasal vaccine for influenza.

“Dr Maltais has extensive experience in vaccine development from both academia and industry,” said the company's CEO Hans Arwidsson.

“Her expertise in vaccine delivery and adjuvants is extremely valuable to the company and with her industry background we can run our projects with an even stronger commercial focus.”

This includes several years at Cyto Pulse Sciences, where she served as manager EU operations and then VP, corporate development.

Berglund had been in her previous position since 2009, and has prior business development experience at both Biovitrum and Avaris.

25th September 2012

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics